2025-08-29 01:31:25
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Jubilant Pharmova Ltd Q1FY22 consolidated net profit drops QoQ to Rs. 160.49 crores
Posted On : 2021-07-23 17:30:05( TIMEZONE : IST )
JUBILANT Pharmova LIMITED has reported financial results for the period ended June 30, 2021.
Financial Results (Q1 FY 2021-22) - QoQ Comparison
The company has reported total income of Rs.1638.54 crores during the period ended June 30, 2021 as compared to Rs.1586.47 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.160.49 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.213.65 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.10.09 for the period ended June 30, 2021 as compared to Rs.13.43 for the period ended March 31, 2021.
| Financials | Q1 FY2021-22 | Q4 FY20-21 | % Change |
| Total Income | ₹ 1638.54 crs | ₹ 1586.47 crs |  3.28% |
| Net Profit | ₹ 160.49 crs | ₹ 213.65 crs |  -24.88% |
| EPS | ₹ 10.09 | ₹ 13.43 | -24.87% |
Financial Results (Q1 FY 2021-22) - YoY Comparison
The company has reported total income of Rs.1638.54 crores during the period ended June 30, 2021 as compared to Rs.1159.98 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.160.49 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.88.01 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.10.09 for the period ended June 30, 2021 as compared to Rs.5.53 for the period ended June 30, 2020.
| Financials | Q1 FY2021-22 | Q1 FY2020-21 | % Change |
| Total Income | ₹ 1638.54 crs | ₹ 1159.98 crs | 41.26% |
| Net Profit | ₹ 160.49 crs | ₹ 88.01 crs | 82.35% |
| EPS | ₹ 10.09 | ₹ 5.53 | 82.46% |
Commenting on Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova said: "During this quarter, in addition to YoY increase, we also reported sequential improvement in the Specialty Pharma segment with gradual recovery across radiopharmaceuticals, Radiopharmacy and Allergy business. In radiopharmaceuticals, we have enhanced efforts to promote existing products as well as expand our product pipeline with strategic partnerships. With a gradual recovery in nuclear medicine procedures, the turnaround plan of Radiopharmacy business is on track. CMO business continued to benefit from COVID related deals.
Contract Research and Development Services business witnessed strong YoY growth in revenues led by healthy demand from customers. We have doubled our chemistry research capacity and the facility is operational now. Despite COVID-19 related lockdowns, we have been able to ensure continuity in most of our manufacturing operations across all business segments while at the same time ensuring safety of our employees. I take this opportunity to thank all our employees who have worked tirelessly across all our plants and offices to ensure continuity in company's operations, while continuing to serve our global customers."
Shares of JUBILANT Pharmova LIMITED was last trading in BSE at Rs. 696.9 as compared to the previous close of Rs. 715.4. The total number of shares traded during the day was 56389 in over 3924 trades.
The stock hit an intraday high of Rs. 723 and intraday low of 692.15. The net turnover during the day was Rs. 40031423.
